Pain, Pain Acute
Conditions
Keywords
Arylepoxamide, AEAr Agonist, 6TM, Tolerability, Safety, SBS-147, SBS147
Brief summary
This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.
Detailed description
The goal of this clinical trial is to learn about the safety of SBS-147. The main questions it aims to answer are: What medical problems do participants have when taking SBS-147? Researchers will compare SBS-147 to a placebo (a look-alike substance that contains no drug) to see if SBS-147 works to treat acute pain. Participants in the single ascending dose portion will: Take SBS-147 or a placebo one time during the study Stay confined to the clinic for a period of 5 days and undergo tests, blood draws, and questionnaires. Complete an end of study visit on Day 8 Participants in the multiple ascending dose portion will: Take SBS-147 or a placebo one time per day or twice a day for 7 days Stay confined to the clinic for a period of 10 days and undergo tests, blood draws, and questionnaires. Complete an end of study visit on Day 14
Interventions
DRUGSBS-147
Experimental therapeutic
DRUGPlacebo
Placebo comparator
Sponsors
Sparian Biosciences, Inc
National Institutes of Health (NIH)
Altasciences Company Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provision of signed and dated informed consent form (ICF) 2. Healthy adult male or female, aged 18 to 55 years, inclusive, at Screening 3. Body mass index (BMI) within 18.0 kg/m2 to 32.0 kg/m2 inclusively 4. Minimum body weight of at least 50.0 kg at Screening 5. Stated willingness to comply with all study procedures and availability for the duration of the study 6. Females of childbearing potential 7. Healthy, as determined by protocol requirements 8. Non- or ex-smoker for at least 90 days prior to Screening 9. Participant is able and willing to comply with all study protocol procedures and requirements
Exclusion criteria
1. Female who is lactating at Screening 2. Female who is pregnant 3. History of significant hypersensitivity reactions (like angioedema) to any drugs 4. Presence or history of significant surgery that may affect drug bioavailability 5. History of significant CV, pulmonary, hematologic, neurologic, psychiatric, endocrine, infectious, or immunologic disease 6. Meet Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) criteria for lifetime or current substance use disorder for any psychoactive substances other than nicotine or caffeine 7. Showing suicidal tendency as per the C-SSRS administered at screening and clinic admission 8. Any clinically significant illness in the 28 days prior to the first study drug administration 9. Use of any prescription drugs in the 28 days or 5 half-lives, whichever is longer, prior to Screening and until the end of the study, that in the opinion of an Investigator would put into question the status of the participant as healthy 10. Use of opioids, hypnotics, and/or sedatives in the last 30 days prior to screening 11. Routine or chronic use of acetaminophen or nonsteroidal anti-inflammatory drugs for more than 7 of the 20 days during the screening period. 12. Use of St. John's Wort in the 28 days prior to Screening 13. Use of any herbal supplements (including Kratom) the 14 days prior to Screening 14. Intake of an Investigational Product (IP) in the 30 days prior to Screening 15. Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration 16. Positive screening results to HIV Ag/Ab combo, hepatitis B surface antigen or hepatitis C virus Ab tests 17. Any other clinically significant abnormalities in laboratory test results at screening that would, in the opinion of an Investigator and based on clinical judgment, increase the participant's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data 18. Donation of plasma in the 7 days prior to Screening 19. Donation of 1 unit of blood to American Red Cross or equivalent organization or donation of over 500 mL of blood in the 56 days prior to Screening 20. Inclusion in a previous cohort for this clinical study 21. Supine pulse rate less than 45 beats per minute (bpm) or more than 100 bpm at the screening visit 22. Supine systolic blood pressure \< 90 or \> 140 mmHg or diastolic blood pressure \< 40 or \> 90 mmHg at the Screening visit 23. Oxygen saturation (SpO2) below 95% at the Screening visit 24. Presence of out-of-range cardiac interval on the ECG at screening or other clinically significant ECG abnormalities, unless deemed non-significant by an Investigator 25. History of risk factors for Torsades de Pointes, including unexplained syncope, known long QT syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory assessments including hypokalaemia, hypercalcaemia, or hypomagnesaemia 26. Family history of long QT syndrome or Brugada syndrome 27. History of fainting 28. Family history of sudden cardiac death or significant heart disease 29. Known presence or history of gastroesophageal reflux or hiatal hernia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | 8 days | To assess the number of treatment emergent adverse events experienced in participants after a single dose of SBS-147 |
| Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 at ascending doses | 14 days | Assess the number of treatment emergent adverse events experienced by participants of SBS-147 after multiple dose oral administration in healthy adults. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relative plasma exposure of SBS-1000 compared with SBS-147 (SAD) | 0-12 hours, 0-24 hours, and extrapolated to infinity after dosing | Geometric mean ratios (SBS-1000 / SBS-147) for Cmax and AUC |
| Plasma pharmacokinetics of SBS-1000 and SBS-147 following multiple ascending doses | Day 1 (single-dose PK) and Day 7 at steady state over the dosing interval (τ) | Plasma concentrations of SBS-1000 and SBS-147 will be analyzed using noncompartmental methods to characterize single-dose and steady-state pharmacokinetics. |
Countries
United States
Contacts
CONTACTOscar McClyde
STUDY_DIRECTORJeff Reich, MD
Sparian Biosciences
Outcome results
None listed